NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
CNN — Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico. It is the fifth company to launch a large-scale trial of a coronavirus vaccine ...
Hosted on MSN
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results